Employers can use Lilly's platform to connect with different third-party program administrators that help manage obesity ...
Eli Lilly (NYSE:LLY) launched its Employer Connect platform to expand access to its obesity medicine Zepbound through U.S.
A service tailored to people with workplace-based insurance coverage represents a new way for Lilly to bypass insurers and ...
Eli Lilly has officially launched Employer Connect, its direct-to-employer platform for its obesity medications, after ...
With short-term returns turning negative, analysts are reassessing Lilly's high valuation, reminding the market that even ...
March 5 (Reuters) - Eli Lilly said on Thursday it has rolled out a platform to help employers connect with organizations ...
Novo Nordisk A/S remains a Buy despite CagriSema setback; Eli Lilly and Company remains a Hold on valuation. Click for this ...
Eli Lilly's market share in obesity drugs exceeds 60%, but further gains may be capped as competition escalates. Read why LLY ...
Jensen Investment Management, an asset management company based in the US, released its fourth-quarter investor letter for ...
Eli Lilly has been a growth beast in recent years, but its valuation has gotten fairly high along the way.
Eli Lilly released new data on its oral pill, orforglipron, Thursday, showing it's almost as good as Ozempic. The pill may be ...
10don MSN
Eli Lilly launches new form of obesity drug Zepbound with a month’s worth of doses in one pen
Eli Lilly hopes the device can be more convenient for Zepbound users and lead to more people taking the drug.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results